Phase I study to evaluate treatment of worsening heart failure 


Corteria Pharmaceuticals has initiated a Phase I study to evaluate the company’s first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonist, COR-1167, for the treatment of Worsening Heart Failure (WHF). 

COR-1167 is a once-daily subcutaneous CRF2 agonist that has demonstrated substantial protective effects and functional improvement in the heart, vasculature and kidneys in multiple animal models of heart failure. Its mechanism of action offers an opportunity for treating WHF with the goal of alleviating cardiac congestion by restoring and maintaining stable cardiovascular and renal function.

The Phase I trial is a randomised placebo-controlled study with the primary objective of assessing the safety and tolerability of COR-1167 in both healthy volunteers and patients with chronic heart failure. 

“The advancement of our lead CRF2 agonist into the clinic is a significant milestone in our mission to bring novel treatments to patients experiencing the debilitating effects of worsening heart failure,” said Philip Janiak, Founder and CEO of Corteria Pharmaceuticals. “The preclinical data for COR-1167 is very promising and we are excited to determine its therapeutic potential in patients.”

Professor Adriaan Voors, Professor of Cardiology at the University Medical Centre Groningen (Netherlands) and principal investigator of the study, said: “The initiation of this Phase I study with COR-1167, a CRF2 agonist, both in healthy volunteers and patients with heart failure is an important step in potentially reducing the burden of heart failure, especially for patients who experience worsening signs and symptoms despite being treated with currently recommended therapies.” 

The company anticipates completing the Phase I study in the first half of 2025, to be followed by the initiation of a Phase II study in this indication. 

Worsening Heart Failure

The clinical course of heart failure is characterised by periods of clinical stability being frequently interrupted by episodes of worsening symptoms and signs, defined as Worsening Heart Failure. Given the central role of congestion in WHF, loop diuretics are the standard of care treatment.  

However, while effective acutely, these do not improve rehospitalisation rates or patient outcomes. Therefore, WHF remains a critically important unmet medical need that continues to have a major impact on quality of life and imposes a major economic burden on the global healthcare system. 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free